MedTrace Logo

A Phase 3 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis

NCT07136805 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 152

Last updated 2025-08-22

No results posted yet for this study

Summary

This is a multicenter, randomized, single-masked, active-controlled, parallel, Phase III pivotal study in China

Conditions

  • Non-infectious Anterior Uveitis

Interventions

DRUG

VVN461 Ophthalmic Solution 1.0%

1 drop for study eye each time, 6 times daily (Q2h) for 7 days; 4 times daily (QID) for 7 days; 2 times daily (BID) for 7 days; 1 time daily for 7 days

DRUG

1.0% prednisolone acetate

1 drop for study eye each time, 6 times daily (Q2h) for 7 days; 4 times daily (QID) for 7 days; 2 times daily (BID) for 7 days; 1 time daily for 7 days

Sponsors & Collaborators

  • VivaVision Biotech, Inc

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-01
Primary Completion
2026-12-31
Completion
2027-04-30
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07136805 on ClinicalTrials.gov